
Microport Cardioflow Medtech Corp
HKEX:2160

Microport Cardioflow Medtech Corp
MicroPort CardioFlow Medtech Corp. operates as a holding company with interest in developing medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-02-04. The firm is mainly engaged in the development and commercialization of transcatheter and surgical solutions for valvular heart diseases. The firm's main products include the first-generation transcatheter aortic heart valve implantation (TAVI) product VitaFlow and the second-generation TAVI product VitaFlow II. The firm mainly conducts business within the domestic market.